BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeini E, Ofek P, Albeck N, Rodriguez Ajamil D, Neufeld L, Eldar‐boock A, Kleiner R, Vaskovich D, Koshrovski‐michael S, Dangoor SI, Krivitsky A, Burgos Luna C, Shenbach‐koltin G, Goldenfeld M, Hadad O, Tiram G, Satchi‐fainaro R. Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches. Adv Therap 2021;4:2000124. [DOI: 10.1002/adtp.202000124] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Bhargav AG, Domino JS, Chamoun R, Thomas SM. Mechanical Properties in the Glioma Microenvironment: Emerging Insights and Theranostic Opportunities. Front Oncol 2022;11:805628. [DOI: 10.3389/fonc.2021.805628] [Reference Citation Analysis]
2 Delello Di Filippo L, Hofstätter Azambuja J, Paes Dutra JA, Tavares Luiz M, Lobato Duarte J, Nicoleti LR, Olalla Saad ST, Chorilli M. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Eur J Pharm Biopharm 2021;168:76-89. [PMID: 34461214 DOI: 10.1016/j.ejpb.2021.08.011] [Reference Citation Analysis]
3 Zhou Z, Sun T, Jiang C. Recent advances on drug delivery nanocarriers for cerebral disorders. Biomed Mater 2021;16:024104. [PMID: 33455956 DOI: 10.1088/1748-605X/abdc97] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Krivitsky A, Pozzi S, Yeini E, Israeli Dangoor S, Zur T, Golan S, Krivitsky V, Albeck N, Pisarevsky E, Ofek P, Madi A, Satchi-fainaro R. Sulfonated Amphiphilic Poly(α)glutamate Amine—A Potential siRNA Nanocarrier for the Treatment of Both Chemo-Sensitive and Chemo-Resistant Glioblastoma Tumors. Pharmaceutics 2021;13:2199. [DOI: 10.3390/pharmaceutics13122199] [Reference Citation Analysis]
5 Kang RH, Park J, Kim J, Chowdhury T, Oh JH, Kim J, Shin J, Kim M, Park CK, Lee S, Lee JY, Kim D. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomater Sci Eng 2021. [PMID: 34196517 DOI: 10.1021/acsbiomaterials.1c00653] [Reference Citation Analysis]
6 Ljubimov VA, Ramesh A, Davani S, Danielpour M, Breunig JJ, Black KL. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Adv Drug Deliv Rev 2021;:114033. [PMID: 34808227 DOI: 10.1016/j.addr.2021.114033] [Reference Citation Analysis]
7 Heravi Shargh V, Luckett J, Bouzinab K, Paisey S, Turyanska L, Singleton WGB, Lowis S, Gershkovich P, Bradshaw TD, Stevens MFG, Bienemann A, Coyle B. Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue. ACS Appl Mater Interfaces 2021;13:35266-80. [PMID: 34310112 DOI: 10.1021/acsami.1c04164] [Reference Citation Analysis]
8 Pozzi S, Scomparin A, Israeli Dangoor S, Rodriguez Ajamil D, Ofek P, Neufeld L, Krivitsky A, Vaskovich-Koubi D, Kleiner R, Dey P, Koshrovski-Michael S, Reisman N, Satchi-Fainaro R. Meet me halfway: Are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development? Adv Drug Deliv Rev 2021;175:113760. [PMID: 33838208 DOI: 10.1016/j.addr.2021.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]